Influenza

Case Study: Phase II/III Clinical Trial (Influenza)

Therapeutic Area:

Infectious Diseases – Influenza

Study Phase:

Phase II/III | International | Full-Service CRO Support

Background:

The investigational product is an innovative therapy evaluated for the treatment of influenza. Smooth Drug Development supported the Phase II/III clinical trial to assess safety and efficacy, contributing to the development of a potential treatment option for an acute viral infection with strong seasonality impact.

Study Scope & Design:

• Phase II/III clinical trial

• 183 subjects enrolled

• 2 clinical sites

• Rapid enrollment conducted within a 1-month period

Smooth Drug Development Full-Service Solution:

Smooth Drug Development provided comprehensive clinical trial support, including:

• Patient recruitment and enrollment management

• Site activation, monitoring, and performance oversight

• Regulatory and ethics submissions

• Logistics coordination and study material supply

• Ongoing operational and risk management

Key Challenges:

• The study coincided with the end of the influenza season, significantly limiting patient availability

• High risk of delayed enrollment due to seasonal decline in influenza incidence

• Need for rapid decision-making and close coordination with sites

Proactive CRO-Led Approach:

Smooth Drug Development implemented an accelerated operational strategy:

• Close, daily coordination with sites to identify and screen eligible patients

• Rapid site support to maximize enrollment within a limited seasonal window

• Continuous enrollment tracking and proactive issue resolution

• Flexible operational management to respond to fluctuating patient availability

Results & Outcomes:

• Successful enrollment of 220 subjects across 3 sites within one month

• Study timelines maintained despite seasonal constraints

• High-quality clinical data collected under time-sensitive conditions

• Full regulatory and GCP compliance maintained throughout the study

Impact:

This study demonstrates Smooth Drug Development’s ability to manage fast-paced, high-pressure infectious disease trials. The project highlights the CRO’s strength in rapid enrollment execution, operational agility, and effective site collaboration, even under challenging seasonal conditions.